Valuation: Norda ASA

Market Cap 51Cr 5.33Cr 4.67Cr 4.33Cr 3.98Cr 7.51Cr 513.37Cr 7.6Cr 52Cr 20Cr 251.59Cr 20Cr 20Cr 868.69Cr P/E 2023 *
-
P/E 2024 3.26x
Enterprise Value 26Cr 2.75Cr 2.41Cr 2.23Cr 2.05Cr 3.87Cr 264.45Cr 3.92Cr 27Cr 10Cr 129.6Cr 10Cr 10Cr 447.49Cr EV / Sales 2023
-1.24x
EV / Sales 2024 0.4x
Free-Float
6.26%
Yield 2023 *
-
Yield 2024 32.5%
1 day+1.53%
3 months+1.53%
6 months+6.67%
Current year-13.60%
Current year 81
Extreme 81
86.4
1 year 80.1
Extreme 80.1
100
3 years 41
Extreme 41
100
5 years 41
Extreme 41
100
10 years 8
Extreme 8
100
Manager TitleAgeSince
Chief Executive Officer - 08/04/2013
Director TitleAgeSince
Chairman 54 31/01/2014
Director/Board Member 68 20/06/2013
Director/Board Member - -
Change 5-day change 1-year change 3-year change Capi.($)
+1.53%-.--%+8.00%+110.73% 4.58Cr
-0.18%-3.16%+0.43%+14.89% 4.87TCr
+1.61%-0.91%+377.07%+584.68% 3.84TCr
+2.61%+3.96%+9.16%+61.36% 3.45TCr
-1.12%-2.99%+26.84%-11.67% 3.4TCr
-0.58%-2.00%-0.07%+31.08% 2.68TCr
+1.37%-3.90% - - 1.56TCr
+0.71%-0.84%+72.13%+116.76% 1.51TCr
-2.03%+0.96%+13.12%+14.01% 1.42TCr
+0.26%-0.80%+19.33%-32.25% 1.27TCr
Average +0.42%-0.91%+58.45%+98.84% 2.4TCr
Weighted average by Cap. +0.40%-1.53%+76.78%+121.45%

Financials

2023 2024
Net sales 8.69Cr 90.29L 79.14L 73.33L 67.49L 1.27Cr 87Cr 1.29Cr 8.75Cr 3.42Cr 43Cr 3.39Cr 3.32Cr 147.14Cr 37Cr 3.86Cr 3.39Cr 3.14Cr 2.89Cr 5.44Cr 371.99Cr 5.51Cr 37Cr 15Cr 182.31Cr 14Cr 14Cr 629.47Cr
Net income 3.12Cr 32.38L 28.38L 26.3L 24.2L 45.64L 31Cr 46.19L 3.14Cr 1.23Cr 15Cr 1.22Cr 1.19Cr 53Cr 13Cr 1.31Cr 1.15Cr 1.06Cr 97.79L 1.84Cr 125.99Cr 1.87Cr 13Cr 4.96Cr 62Cr 4.91Cr 4.81Cr 213.2Cr
Net Debt -31Cr -3.23Cr -2.83Cr -2.63Cr -2.42Cr -4.56Cr -311.36Cr -4.61Cr -31Cr -12Cr -152.59Cr -12Cr -12Cr -526.87Cr -25Cr -2.58Cr -2.27Cr -2.1Cr -1.93Cr -3.64Cr -248.91Cr -3.69Cr -25Cr -9.8Cr -121.99Cr -9.7Cr -9.49Cr -421.2Cr
Logo Norda ASA
Norda ASA, formerly NorDiag ASA, is a Norway-based company active within the biotechnology sector. It develops, manufactures and markets automated solutions (instruments and tests) for sample preparation of bacterial and human DNA from difficult biological samples for use in the fields of infectious diseases, transplantation testing (HLA Typing) and others. The Company’s products include NorDiag Arrow (CE, IVD), which is a compact, automated solution for nucleic acid extractions, as well as NorDiag Bullet, 8 tip config, which is a fully automated sample preparation instrument for molecular diagnostics and can isolate from samples such as urine, swab, faces, sputum and blood. Its distribution products include Molzym GmbH and Co KG, as well as Hain Lifescience GmbH. Its customers are clinical laboratories, hospitals, research institutes, medical diagnostics and healthcare providers. It is operational through offices and laboratories in Norway, Sweden, Austria and the United States.
Employees
1
  1. Stock Market
  2. Stocks
  3. NORD Stock